India’s Lupin Set For Global Generics Growth; Logs 53 Percent Profit Jump In Q2
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Indian drug maker Lupin said it was poised to grow further in the global generics market as it reported a 53 percent jump in consolidated quarterly net profit, driven by a strong across-the-board performance
You may also be interested in...
Lupin Buys Stake In South Africa’s Pharma Dynamics; Aims To Be In Top 3
MUMBAI - After months of negotiations, Indian generic drug maker Lupin acquired a 60 percent equity stake in South Africa's sixth largest generic drug maker Pharma Dynamics with the goal of joining the top ranks of companies in South Africa in three years
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).